デフォルト表紙
市場調査レポート
商品コード
963560

幹細胞臍帯血の世界市場 - 機会分析・業界予測 (2020-2027年):ストレージサービス・治療・アプリケーション別

Stem Cell Umbilical Cord Blood Market by Storage Service, Therapeutics, and Application: Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 209 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.65円
幹細胞臍帯血の世界市場 - 機会分析・業界予測 (2020-2027年):ストレージサービス・治療・アプリケーション別
出版日: 2020年08月10日
発行: Allied Market Research
ページ情報: 英文 209 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界における幹細胞臍帯血の市場規模は、2019年の31億1080万米ドルから、2027年までに101億3520万米ドルへ達すると予測され、2020年から2027年にかけては、16.9%のCAGRを記録する見込みです。

現在、世界の幹細胞市場は、信頼性がありコスト効果的な治療法、および副作用が少ないことから、ヘルスケア業界において支配的です。臍帯血幹細胞セグメントは、幹細胞市場の潜在的なセグメントの1つであり、将来的に成長すると予測されています。臍帯血は幹細胞の豊富な供給源の1つであり、妊娠または出産後に老廃物として扱われます。しかし、この血液は、癌、糖尿病、血液疾患の免疫疾患などの慢性疾患を治療する大きな可能性を秘めています。

当レポートでは、世界の幹細胞臍帯血市場について調査し、市場の概要とダイナミクス、各セグメント・地域別による市場規模の分析と予測、および主要企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
    • 促進要因
      • サービスの多様化
      • 遺伝子検査、生殖能力、および生殖支援サービス
      • 慢性疾患の治療
      • 支出能力と適切な支払い計画の増加
    • 抑制要因
      • 収集中の法的および倫理的問題
      • 高額な治療費
      • 適切な一致したドナーが利用できない
    • 市場機会
      • 治療用途の進歩
      • 公的ストレージのための資金の増加
    • 幹細胞臍帯血市場のバリューチェーン分析
  • 主要企業のポジショニング

第4章 幹細胞臍帯血市場:ストレージサービス別

  • 概要
    • 市場規模と予測
  • 公的臍帯血バンク
    • 概要
    • 主要な成長動向と機会
    • 市場規模と予測
    • 市場分析:国別
  • 民間臍帯血バンク
    • 概要
    • 主要な成長動向と機会
    • 市場規模と予測
    • 市場分析:国別
  • ハイブリッド臍帯血バンク
    • 概要
    • 市場規模と予測
    • 市場分析:国別

第5章 幹細胞臍帯血市場:治療別

  • 概要
    • 市場規模と予測
    • 概要
    • 市場規模と予測
    • 市場分析:国別
  • 糖尿病
  • 血液疾患
  • 免疫障害
  • 代謝障害
  • その他

第6章 幹細胞臍帯血市場:アプリケーション別

  • 概要
    • 市場規模と予測
  • 移植医学
    • 概要概要
    • 市場規模と予測
    • 市場分析:国別
  • 再生医療

第7章 幹細胞臍帯血市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主要な市場動向と機会
    • 市場規模と予測:国別
    • 市場規模と予測:ストレージサービス別
    • 市場規模と予測:治療別
    • 市場規模と予測:アプリケーション別
    • 米国
      • 米国の市場規模と予測:ストレージサービス別
      • 米国の市場規模と予測:治療別
      • 米国の市場規模と予測:アプリケーション別
    • カナダ
    • メキシコ
  • 欧州
    • 欧州の市場規模と予測:国別
    • 欧州の市場規模と予測:ストレージサービス別
    • 欧州の市場規模と予測:治療別
    • 欧州の市場規模と予測:アプリケーション別
    • 英国
      • 英国の市場規模と予測:ストレージサービス別
      • 英国の市場規模と予測:治療別
      • 英国の市場規模と予測:アプリケーション別
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 主要な市場動向と機会
    • アジア太平洋市場の規模と予測:国別
    • アジア太平洋市場の規模と予測:ストレージサービス別
    • アジア太平洋市場の規模と予測:治療別
    • アジア太平洋市場の規模と予測:アプリケーション別
    • 日本
      • 日本の市場規模と予測:ストレージサービス別
      • 日本の市場規模と予測:治療別
      • 日本の市場規模と予測:アプリケーション別
    • 中国
    • インド
    • その他アジア太平洋地域
  • LAMEA
    • 主要な市場動向と機会
    • LAMEAの市場規模と予測:国別
    • LAMEAの市場規模と予測:ストレージサービス別
    • LAMEAの市場規模と予測:治療別
    • LAMEAの市場規模と予測:アプリケーション別
    • ブラジル
      • ブラジルの市場規模と予測:ストレージサービス別
      • ブラジルの市場規模と予測:治療別
      • ブラジルの市場規模と予測:アプリケーション別
    • 南アフリカ
    • サウジアラビア
    • その他LAMEA

第8章 企業プロファイル

  • Americord Registry LLC
  • China Cord Blood Corporation
  • Cord Blood America, Inc.
  • Cordlife Group Limited
  • Cryo-Cell International, Inc.
  • Esperite N.V.
  • LifeCell International Pvt. Ltd.
  • Medipost Co. Ltd.
  • ViaCord
  • Vita34 AG
図表

LIST OF TABLES

  • TABLE 01.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 02.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY PUBLIC CORD BLOOD STORAGE, 2019-2027 ($MILLION)
  • TABLE 03.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY PRIVATE CORD BLOOD STORAGE, 2019-2027 ($MILLION)
  • TABLE 04.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY HYBRID CORD BLOOD STORAGE, 2019-2027 ($MILLION)
  • TABLE 05.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS , 2019-2027 ($MILLION)
  • TABLE 06.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR CANCER , 2019-2027 ($MILLION)
  • TABLE 07.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR DIABETES 2019-2027 ($MILLION)
  • TABLE 08.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 09.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR IMMUNE DISORDERS, 2019-2027 ($MILLION)
  • TABLE 10.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR METABOLIC DISORDERS, 2019-2027 ($MILLION)
  • TABLE 11.GLOBAL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY TYPE OF IMMUNE DISORDERS, 2019-2027 ($MILLION)
  • TABLE 12.GLOBAL STEM CELL UMBILICIAL CORD BLOOD MARKET FOR OTHERS 2019-2027 ($MILLION)
  • TABLE 13.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 14.STEM CELL UMBILICIAL CORD BLOOD MARKET, FOR TRANSPLANT MEDICINE , 2019-2027 ($MILLION)
  • TABLE 15.STEM CELL UMBILICIAL CORD BLOOD MARKET, FOR REGENERATIVE MEDICINE , 2019-2027 ($MILLION)
  • TABLE 16.STEM CELL UMBLICIAL CORD BLOOD MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019 -2026 ($MILLION)
  • TABLE 18.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 19.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2026 ($MILLION)
  • TABLE 20.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2026 ($MILLION)
  • TABLE 21.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 22.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2026 ($MILLION)
  • TABLE 23.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 24.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 25.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 26.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 27.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 28.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 29.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 30.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 31.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 32.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 33.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 34.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 35.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2020 ($MILLION)
  • TABLE 36.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 37.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 38.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 39.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 40.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 41.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019S-2027 ($MILLION)
  • TABLE 42.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 43.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 44.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 45.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 46.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 47.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 48.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 49.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 50.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 51.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 52.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 53.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 54.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 55.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 56.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 57.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 58.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 59.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 60.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 61.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 62.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 63.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 64.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 65.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 66.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 67.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 68.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 69.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 70.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 71.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 72.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 73.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 74.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 75.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 76.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 77.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 78.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 79.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 80.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 81.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019-2027 ($MILLION)
  • TABLE 82.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019-2027 ($MILLION)
  • TABLE 83.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 84.AMERICORD REGISTRY LLC: COMPANY SNAPSHOT
  • TABLE 85.AMERICORD: OPERATING SEGMENTS
  • TABLE 86.CRYO-CELL INTERNATIONALS: PRODUCT PORTFOLIO
  • TABLE 87.CHINA CORD BLOOD CORPORATION: COMPANY SNAPSHOT
  • TABLE 88.CHINA CORD BLOOD CORPORATION: OPERATING SEGMENTS
  • TABLE 89.CORD BLOOD AMERICA: COMPANY SNAPSHOT
  • TABLE 90.CORD BLOOD AMERICA: OPERATING SEGMENTS
  • TABLE 91.CORDLIFE GROUP LIMITED: COMPANY SNAPSHOT
  • TABLE 92.CORDLIFE GROUP LIMITED: OPERATING SEGMENTS
  • TABLE 93.CORDLIFE: PRODUCT PORTFOLIO
  • TABLE 94.CORDLIFE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95.CRYO-CELL INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 96.CRYO-CELL INTERNATIONALS: OPERATING SEGMENTS
  • TABLE 97.CRYO-CELL INTERNATIONALS OFFERS FOLLOWING SERVICES:CRYO-CELL INTERNATIONALS: PRODUCT PORTFOLIO
  • TABLE 98.ESPERITE: COMPANY SNAPSHOT
  • TABLE 99.ESPERITE: OPERATING SEGMENTS
  • TABLE 100.ESPERITE : PRODUCT PORTFOLIO
  • TABLE 01.LIFECELL: COMPANY SNAPSHOT
  • TABLE 02.LIFECELL: OPERATING SEGMENTS
  • TABLE 03.LIFECELL: PRODUCT PORTFOLIO
  • TABLE 04.MEDIPOST CO. LTD: COMPANY SNAPSHOT
  • TABLE 05.MEDIPOST CO. LTD: OPERATING SEGMENTS
  • TABLE 06.MEDIPOST CO. LTD: PRODUCT PORTFOLIO
  • TABLE 07.MEDIPOST CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 01.VIACORD : COMPANY SNAPSHOT
  • TABLE 02.VITA34 INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 03.VIACORD: PRODUCT PORTFOLIO
  • TABLE 04.VITA34 INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 05.VITA34 INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 06.VITA34 INTERNATIONAL: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.TOP PLAYER POSITIONING, 2019
  • FIGURE 02.COMPARATIVE SHARE ANALYSIS FOR PUBLIC CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 03.COMPARATIVE SHARE ANALYSIS OF PRIVATE CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 04.COMPARATIVE SHARE ANALYSIS OF HYBRID CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 05.COMPARATIVE SHARE ANALYSIS OF CANCER MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 06.COMPARATIVE SHARE ANALYSIS OF DIABETES MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 07.COMPARATIVE SHARE ANALYSIS OF BLOOD DISEASES MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 08.COMPARATIVE SHARE ANALYSIS OF IMMUNE DISORDERS MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 09.COMPARATIVE SHARE ANALYSIS OF METABOLIC DISORDERS MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 10.COMPARATIVE SHARE ANALYSIS OF OTHERS MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 11.COMPARATIVE SHARE ANALYSIS OF TRANSPLANT MEDICINE MARKET BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF REGENERATIVE MEDICINE MARKET BY COUNTRY, 2019 & 2027 (%)

CHINA CORD BLOOD CORPORATION: NET SALES, 2017-2019 ($MILLION)

CORDLIFE GROUP LIMITED: NET SALES, 2017-2018 ($MILLION)

CORDLIFE: REVENUE SHARE BY SEGMENT, 2018 (%)

CRYO-CELL INTERNATIONAL: NET SALES, 2016-2018 ($MILLION)

CRYO CELL INTERNATIONALS: REVENUE SHARE BY SEGMENTS, 2018 (%)

MEDIPOST CO. LTD: NET SALES, 2017-2018 ($MILLION)

VITA34 INTERNATIONAL: NET SALES, 2017-2018 ($MILLION)

目次
Product Code: A00037

Title:
Stem Cell Umbilical Cord Blood Market by Storage Service (Public Cord Blood Banks, Private Cord Blood Banks, and Hybrid Cord Blood Banks), Therapeutics (Cancer, Diabetes, Blood Diseases, Immune Disorders, Metabolic Disorders, and Other Diseases), and Application( Transplant Medicine and Regenerative Medicine): Global Opportunity Analysis and Industry Forecast, 2020-2027 .

The global stem cell umbilical cord blood market was valued at $3,110.8 million in 2019, and is projected to reach $10,135.20 million by 2027, registering a CAGR of 16.9% from 2020 to 2027.

Presently, the global stem cell market dominates the healthcare industry with its reliable and cost-effective methods of treatment and fewer side effects. The umbilical cord blood stem cell segment is one of the potential segments of the stem cell market, which is projected to grow in the future. Cord blood is one of the rich sources of stem cells, which are treated as waste after pregnancy or childbirth; however, this blood has huge potential to treat chronic diseases such as cancer, diabetes, and blood disease immune diseases.

Currently, more than 80 genetic diseases can be treated with cord blood and the blood is rich source of hematopoietic stem cells. Various governments are supporting the research and clinical trials of cord blood stem cells, which is has increased the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. However, competition in the market is intense with companies trying to create brand awareness, therefore, compelling market players to adopt many market-based strategies. These stem cells are the only type of cells that are stored in controlled conditions due to their lower volume and higher cell count.

Cost structure of the stem cell treatment has a major impact on the growth of the market in developed countries. Stem cells collected from cord blood are used in treatment of many rare diseases that include metabolic diseases and immune diseases. The overall stem cell umbilical cord blood market is growing from clinical applications to commercialization. Companies involved in the research and commercialization of stem cell therapies are adopting approval and clinical trials as their primary strategy and product launch as their secondary strategy.

Based on the storage services, the market is segmented into private cord blood banks, public cord blood banks and hybrid cord blood banks. The private cord banks segment was the highest contributor to the market, with $1,537 million in 2019, and is estimated to reach $4,765.90 million by 2027, at a CAGR of 15.3% during the forecast period.

Based on therapeutics, the market is categorized into Cancer, Diabetes, Blood diseases, Immune disorders, Metabolic disorders and other diseases. The diabetes segment was the highest contributor to the market, with $794 million in 2019, and is estimated to reach $2,655.58 million by 2027, at a CAGR of 16.4% during the forecast period.

Based on application, the market is categorized into transplant medicine and regenerative medicine. The regenerative medicine segment was the highest contributor to the market, with $1,854.12 million in 2019, and is estimated to reach $5,878.55 million by 2027, at a CAGR of 15.6% during the forecast period.

The stem cell umbilical cord blood market is more lucrative in North America and European countries. Most patents granted for cord blood were from the U.S. and European authorities. North America shared the largest revenue of $1,353.20 million in 2019, however Asia-Pacific is expected to grow at CAGR of 16.7% CAGR during the forecast period.

The companies offering stem cell umbilical cord blood storage services include Cordlife Group Limited, Cord Blood America, Cryo-Cell International, Medipost, Global Cord Blood Corporation, Americord Registry, and Cordvida.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current stem cell umbilical cord blood trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.

The market forecast is studied from 2020 to 2027.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Storage services

  • Public Cord Blood Banks
  • Private Cord Blood Banks
  • Hybrid Cord Blood Banks

By Therapeutics

  • Cancer
  • Diabetes
  • Blood Diseases
  • Immune Disorders
  • Metabolic Disorders
  • Other Diseases

By Application

  • Transplant Medicine
  • Regenerative Medicine

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
  • Key players in the market
  • Cordlife Group Limited
  • Cord Blood America
  • Cryo-Cell International
  • Medipost
  • Americord Registry
  • Esperite
  • China Cord Blood Corporation
  • LifeCell Inetrnational
  • ViaCord
  • Vita34 AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Research methodology
    • 1.3.1.Secondary research
    • 1.3.2.Primary research
    • 1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
    • 3.1.1.Drivers
      • 3.1.1.1.Diversification of services
      • 3.1.1.2.Genetic testing, fertility, and reproduction assisted services
      • 3.1.1.3.Treatment for chronic diseases
      • 3.1.1.4.Rise in spending capacity and suitable payment plans
    • 3.1.2.Restraints
      • 3.1.2.1.Legal and ethical issues during collection
      • 3.1.2.2.Higher cost of therapies
      • 3.1.2.3.Unavailability of suitable matched donor
    • 3.1.3.Opportunities
      • 3.1.3.1.Advancements in therapeutic applications
      • 3.1.3.2.Rise in funds for public storage
    • 3.1.4.Value chain analysis of stem cell umbilical cord blood market
  • 3.2.Top Player Positioning, 2019

CHAPTER 4:STEM CELL UMBILICAL CORD BLOOD MARKET, BY STORAGE SERIVCES

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Public Cord Blood Banks
    • 4.2.1.Overview
    • 4.2.2.Key growth trends and opportunities
    • 4.2.3.Market size and forecast
    • 4.2.4.Market analysis, by country
  • 4.3.Private Cord Blood Banks
    • 4.3.1.Overview
    • 4.3.2.Key growth trends and opportunities
    • 4.3.3.Market size and forecast
    • 4.3.4.Market analysis, by country
  • 4.4.Hybrid Cord Blood Banks
    • 4.4.1.Overview
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country

CHAPTER 5:STEM CELL UMBILICAL CORD BLOOD MARKET, BY THERAPEUTICS

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Cancer
    • 5.2.1.Overview
    • 5.2.2.Market size and forecast
    • 5.2.3.Market analysis, by country
  • 5.3.Diabetes
    • 5.3.1.Overview
    • 5.3.2.Market size and forecast
    • 5.3.3.Market analysis, by country
  • 5.4.Blood diseases
    • 5.4.1.Overview
    • 5.4.2.Market size and forecast
    • 5.4.3.Market analysis, by country
  • 5.5.Immune Disorders
    • 5.5.1.Overview
    • 5.5.2.Market size and forecast
    • 5.5.3.Market analysis, by country
  • 5.6.Metabolic Disorders
    • 5.6.1.Overview
    • 5.6.2.Market size and forecast
    • 5.6.3.Market analysis, by country
  • 5.7.Others
    • 5.7.1.Overview
    • 5.7.2.Market size and forecast
    • 5.7.3.Market analysis, by country

CHAPTER 6:STEM CELL UMBILICAL CORD BLOOD MARKET, BY APPLICATION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Transplant Medicine
    • 6.2.1.Overview
    • 6.2.2.Market size and forecast
    • 6.2.3.Market analysis, by country
  • 6.3.Regenerative Medicine
    • 6.3.1.Overview
    • 6.3.2.Market size and forecast
    • 6.3.3.Market analysis, by country

CHAPTER 7:STEM CELL UMBILICAL CORD BLOOD MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends and opportunities
    • 7.2.2.Market size and forecast, by country
    • 7.2.3.Market size and forecast, by storage service
    • 7.2.4.Market size and forecast, by therapeutics
    • 7.2.5.Market size and forecast, by application
    • 7.2.6.U.S.
      • 7.2.6.1.U.S. market size and forecast, by storage service
      • 7.2.6.2.U.S. market size and forecast, by therapeutics
      • 7.2.6.3.U.S. market size and forecast, by application
    • 7.2.7.Canada
      • 7.2.7.1.Canada market size and forecast, by storage service
      • 7.2.7.2.Canada market size and forecast, by therapeutics
      • 7.2.7.3.Canada market size and forecast, by application
    • 7.2.8.Mexico
      • 7.2.8.1.Mexico market size and forecast, by storage service
      • 7.2.8.2.Mexico market size and forecast, by therapeutics
      • 7.2.8.3.Mexico market size and forecast, by application
  • 7.3.Europe
    • 7.3.1.Europe market size and forecast, by country
    • 7.3.2.Europe market size and forecast, by storage service
    • 7.3.3.Europe market size and forecast, by therapeutics
    • 7.3.4.Europe market size and forecast, by application
    • 7.3.5.UK
      • 7.3.5.1.UK market size and forecast, by storage service
      • 7.3.5.2.UK market size and forecast, by therapeutics
      • 7.3.5.3.UK market size and forecast, by application
    • 7.3.6.France
      • 7.3.6.1.France market size and forecast, by storage service
      • 7.3.6.2.France market size and forecast, by storage service
      • 7.3.6.3.France market size and forecast, by therapeutics
      • 7.3.6.4.France market size and forecast, by application
    • 7.3.7.Germany
      • 7.3.7.1.Germany market size and forecast, by storage service
      • 7.3.7.2.Germany market size and forecast, by therapeutics
      • 7.3.7.3.Germany market size and forecast, by application
    • 7.3.8.Italy
      • 7.3.8.1.Italy market size and forecast, by storage service
      • 7.3.8.2.Italy market size and forecast, by therapeutics
      • 7.3.8.3.Italy market size and forecast, by application
    • 7.3.9.Spain
      • 7.3.9.1.Spain market size and forecast, by storage service
      • 7.3.9.2.Spain market size and forecast, by therapeutics
      • 7.3.9.3.Spain market size and forecast, by application
    • 7.3.10.Rest of Europe
      • 7.3.10.1.Rest of Europe market size and forecast, by storage service
      • 7.3.10.2.Rest of Europe market size and forecast, by therapeutics
      • 7.3.10.3.Rest of Europe market size and forecast, by application
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends and opportunities
    • 7.4.2.Asia-Pacific market size and forecast, by country
    • 7.4.3.Asia-Pacific market size and forecast, by storage service
    • 7.4.4.Asia-Pacific market size and forecast, by therapeutics
    • 7.4.5.Asia-Pacific market size and forecast, by application
    • 7.4.6.Japan
      • 7.4.6.1.Japan market size and forecast, by storage service
      • 7.4.6.2.Japan market size and forecast, by therapeutics
      • 7.4.6.3.Japan market size and forecast, by application
    • 7.4.7.China
      • 7.4.7.1.China market size and forecast, by storage service
      • 7.4.7.2.China market size and forecast, by therapeutics
      • 7.4.7.3.China market size and forecast, by application
    • 7.4.8.India
      • 7.4.8.1.India market size and forecast, by storage service
      • 7.4.8.2.India market size and forecast, by therapeutics
      • 7.4.8.3.India market size and forecast, by application
    • 7.4.9.Rest of Asia-Pacific
      • 7.4.9.1.Rest of Asia-Pacific market size and forecast, by storage service
      • 7.4.9.2.Rest of Asia-Pacific market size and forecast, by therapeutics
      • 7.4.9.3.Rest of Asia-Pacific market size and forecast, by application
  • 7.5.LAMEA
    • 7.5.1.Key market trends and opportunities
    • 7.5.2.LAMEA market size and forecast, by country
    • 7.5.3.LAMEA market size and forecast, by storage service
    • 7.5.4.LAMEA market size and forecast, by therapeutics
    • 7.5.5.LAMEA market size and forecast, by application
    • 7.5.6.Brazil
      • 7.5.6.1.Brazil market size and forecast, by storage service
      • 7.5.6.2.Brazil market size and forecast, by therapeutics
      • 7.5.6.3.Brazil market size and forecast, by application
    • 7.5.7.South Africa
      • 7.5.7.1.South Africa market size and forecast, by storage service
      • 7.5.7.2.South Africa market size and forecast, by therapeutics
      • 7.5.7.3.South Africa market size and forecast, by application
    • 7.5.8.Saudi Arabia
      • 7.5.8.1.Saudi Arabia market size and forecast, by storage service
      • 7.5.8.2.Saudi Arabia market size and forecast, by therapeutics
      • 7.5.8.3.Saudi Arabia market size and forecast, by application
    • 7.5.9.Rest of LAMEA
      • 7.5.9.1.Rest of LAMEA market size and forecast, by storage service
      • 7.5.9.2.Rest of LAMEA market size and forecast, by therapeutics
      • 7.5.9.3.Rest of LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

  • 8.1.Americord Registry LLC
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
  • 8.2.China Cord Blood Corporation
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Business performance
  • 8.3.Cord Blood America, Inc.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
  • 8.4.Cordlife Group Limited
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.Cryo-Cell International, Inc.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.Esperite N.V.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
  • 8.7.LifeCell International Pvt. Ltd.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
  • 8.8.Medipost Co. Ltd.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.ViaCord
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
  • 8.10.Vita34 AG
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance